Researchers study immune system dysfunction in non-Hodgkin’s lymphoma (NHL) through a variety of detailed and multifaceted approaches that combine clinical observations, laboratory experiments, and advanced molecular techniques. Their goal is to understand how the immune system is altered by the…
Non-Hodgkin’s lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. Detecting NHL through blood tests alone is not straightforward or definitive, but blood tests do play an important role…
Detecting non-Hodgkin’s lymphoma (NHL) early relies heavily on identifying specific biomarkers—biological molecules that indicate the presence of cancerous activity in the body. These biomarkers can be found in blood, tissue, or other bodily fluids and help doctors diagnose NHL before…
Non-Hodgkin’s lymphoma (NHL) survivors may face a higher risk of developing dementia compared to the general population, though this relationship is complex and influenced by multiple factors. NHL is a type of blood cancer affecting lymphocytes, and advances in treatment…
Non-Hodgkin’s lymphoma (NHL) research addresses relapse prevention through a multifaceted approach that combines improved understanding of disease biology, risk stratification, novel therapies, and tailored treatment strategies aimed at reducing the chance of the cancer returning after initial remission. Relapse in…
Targeted therapies play a transformative and increasingly central role in non-Hodgkin’s lymphoma (NHL) research, revolutionizing how this diverse group of blood cancers is understood and treated. Unlike traditional chemotherapy, which broadly attacks rapidly dividing cells, targeted therapies are designed to…
Immunotherapy has emerged as a powerful new approach in cancer treatment, including for non-Hodgkin’s lymphoma (NHL), by harnessing the body’s own immune system to identify and destroy cancer cells. Unlike chemotherapy, which directly attacks rapidly dividing cells but can also…
Researchers study the link between non-Hodgkin’s lymphoma (NHL) and aging through a variety of approaches that combine clinical data, biological investigations, and population-level analyses. This multifaceted research aims to understand how aging influences the development, progression, and treatment outcomes of…
Non-Hodgkin’s lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the body’s immune system. While the exact causes of NHL are not fully understood, it is known that a combination of genetic,…
Non-Hodgkin’s lymphoma (NHL) is a diverse group of cancers that originate from the lymphatic system, which is part of the immune system. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell. The progression of…